PRESS RELEASE | Metcela Inc.
-
PRESS RELEASE
Metcela Inc. Completes the Series C Financing of Total $14 Million
Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.
-
PRESS RELEASE
Metcela acquires Japan Regenerative Medicine Co., Ltd., developing cardiac stem cell-based therapy
Through this acquisition, Metcela will add an autologous cell product for pediatric congenital heart disease to its pipeline and significantly strengthen its clinical development infrastructure for regenerative medicine products.
-
PRESS RELEASE
Metcela Raises Funds from Two University Venture Capitals
Metcela intends to significantly strengthen its collaboration with Osaka University and Tohoku University in its future development activities through this financing.
-
NEWS
Metcela announces issuance of second Japanese patent covering fibroblast-based cell therapy for the treatment of heart diseases
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6618066 to support the company’s technology of VCF (VCAM-1-positive Cardiac Fibroblast).
